Neuropediatrics 2021; 52(02): 153
DOI: 10.1055/s-0040-1716904
Letter to the Editor

Letter to the Editor Regarding the Article “Whole-Exome Sequencing in NF1-Related West's Syndrome Leads to the Identification of KCNC2 as a Novel Candidate Gene for Epilepsy”

1  Oasi Research Institute-IRCCS, Troina, Italy
2  Department of Sciences for Health Promotion and Mother and Child Care “G. D'Alessandro” University of Palermo, Palermo, Italy
,
Francesco Calì
1  Oasi Research Institute-IRCCS, Troina, Italy
,
Mirella Vinci
2  Department of Sciences for Health Promotion and Mother and Child Care “G. D'Alessandro” University of Palermo, Palermo, Italy
,
Carmelo Amato
1  Oasi Research Institute-IRCCS, Troina, Italy
,
Michele Roccella
3  Department of Psychology, Educational Science and Human Movement, University of Palermo, Palermo, Italy
,
Tiziana Granata
4  Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
,
Elena Freri
4  Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
,
Roberta Solazzi
4  Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
,
Valentino Romano
5  Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy
,
Maurizio Elia
1  Oasi Research Institute-IRCCS, Troina, Italy
› Author Affiliations

We read with interest the short communication by Rademache et al,[1] particularly addressing the whole-exome sequencing (WES) reevaluation of patients with neurofibromatosis type 1 (NF1).

This article provides an interesting suggestion about how a systematic genetic analysis could find potentially secondary genetic etiologies in patients with NF1, and we believe that this approach could be extended to other diseases.

The authors identified a de novo variant in KCNC2 gene (c.G499T and p.D167Y) coding for Kv3.2 potassium channel in a patient with NF1 and suggested that this mutation could play a role in the pathogenesis of drug-resistant epilepsy of this subject. The authors also assume that Kv3.2 was previously undescribed in literature as correlated to epilepsy.

However, at Oasi Research Institute-IRCCS (Troina, Italy), we had previously identified a heterozygous de novo variant c.1411G > C (p.Val471Leu) in the KCNC2 gene in a patient with early severe developmental and epileptic encephalopathy.[2] The first online version of our article was published on January 20, 2020 but Rademache et al and reviewers must have missed it before the publication of their work.

The research of Rademache et al confirmed the likely dominant inheritance of KCNC2 gene and suggested a broad phenotype related to KCNC2 variants. We hope that a larger genotype–phenotype correlation study, taking into account the existing literature data, will be able to shed light on the implications of KCNC2 mutations.



Publication History

Received: 10 June 2020

Accepted: 23 July 2020

Publication Date:
27 October 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany